Conference Coverage

How does the immune microenvironment change as EGFR-mutant lung adenocarcinoma develops treatment resistance and undergoes histologic transformation? In a recent study, multiomic spatial findings revealed broad immune suppression following transformation, including changes in T cells and immunosuppressive macrophages. Learn more with Dr. Triparna Sen, who shared these new findings at the 2026 World Conference on Lung Cancer. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

The 2026 World Conference on Lung Cancer (WCLC) is set to spotlight pivotal research that could inform the next chapter of lung cancer care. Dr. Triparna Sen previews key phase III trials across small cell and non-small cell lung cancer, including emerging data on antibody-drug conjugates, targeted therapies, MRI surveillance, and adjuvant treatment, as well as sessions focused on biomarkers and liquid biopsy. Dr. Sen is the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

The 2026 World Conference on Lung Cancer (WCLC) is bringing together leaders, emerging investigators, and educational opportunities from across the lung cancer field. Dr. Triparna Sen sat down with us to share her perspective on how early-career clinicians and researchers can get the most out of their WCLC experience. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Earlier recognition of ATTR-CM remains a challenge, but emerging applications of AI could offer a new way to raise clinical suspicion. Dr. Bruno Batinica, a Postdoctoral Associate at the Yale School of Medicine, explores how AI models could identify patterns in ECG and echocardiography that may help flag patients for further evaluation.

Could multimodal AI help identify patients with transthyretin amyloid cardiomyopathy (ATTR-CM) who might otherwise go undiagnosed? Dr. Bruno Batinica, a Postdoctoral Associate at the Yale School of Medicine, joins us to share early findings from the TRACE-AI study, including AI-enabled model performance across diverse health systems, the potential value of combining modalities to improve positive predictive value, and next steps toward prospective deployment in clinical practice.

Cardiovascular risk in women can emerge well before older age, but traditional approaches to risk assessment may overlook sex-specific factors in patients under 65. Dr. Noel Bairey Merz joins us to share how tools such as the PREVENT score and coronary artery calcium scoring, along with obstetric history and female-dominant conditions, can help us identify elevated risk earlier. Dr. Bairey Merz is the Director of the Barbra Streisand Women’s Health Center, the Linda Joy Pollin Women’s Heart Health Program, and the Preventive and Rehabilitative Cardiac Center at the Cedars-Sinai Smidt Heart Institute in Beverly Hills, California. She also spoke about this topic at the 2026 European Society of Cardiology Congress.

For patients with diabetes, effective care requires more than just lowering A1C. Dr. Scott Isaacs joins us to discuss the importance of incorporating comorbidities into care and strategies for systematic screening and follow-up. He’s the Immediate Past President of the American Association of Clinical Endocrinology and an Associate Professor of Medicine at Emory University School of Medicine.

For patients with type 2 diabetes, the latest American Association of Clinical Endocrinology (AACE) guidance supports tailoring hypertension treatment to individual risk profiles. Dr. Scott Isaacs joins us to review updated blood pressure targets, first-line therapies, and management considerations for patients at increased risk. He's the Immediate Past President of the AACE and an Associate Professor of Medicine at Emory University School of Medicine.

From fracture liaison services to menopause care, the 2026 Interdisciplinary Symposium on Osteoporosis (ISO) covered the latest advances and interdisciplinary strategies in bone health. Join Marshall Miller and Ami Patel, Vice President of Science and Education at the Bone Health and Osteoporosis Foundation, for a recap of this year's meeting.

New findings from the SYNCHRONIZE-1 trial reveal that survodutide's impact extends beyond weight reduction, with a demonstrated decrease in liver fat and meaningful improvements across multiple markers of metabolic health in patients without type 2 diabetes. Dr. Carel le Roux joins us to share the efficacy and safety data and explore what these results could mean for the future of metabolic disease management. Dr. Le Roux is the Director of the Metabolic Medicine Group and a Professor of Chemical Pathology in the School of Medicine at University College Dublin, and he presented these findings at the 2026 American Diabetes Association Scientific Sessions.